Across TCGA pan-cancer cohorts, AADACL2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AADACL2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher AADACL2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AADACL2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, BLCA, and LUSC are the cancer types where AADACL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BLCA	OS	Median	III,IV	0.057	0.684	<.001	24	view →
LUSC	OS	Median	II,III,IV	0.140	0.743	.001	24	view →
UCEC	DFS	Median	All	0.969	0.829	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AADACL2 tumor-vs-normal RNA expression · all AADACL2 data types